

CURRICULUM VITAE
Ruth Oratz, M.D., F.A.C.P.

Office Address: The Women's Oncology & Wellness Practice
345 East 37th Street
Suite 202
New York, New York 10016

Office Telephone: 212-400-4904

Office Fax: 212-400-4908

Email: ruthoratz@thewomenspractice.md
ruth.oratz@med.nyu.edu

Website: www.thewomenspractice.md

Place of Birth: New York

EDUCATION

Radcliffe College, Harvard University Cambridge, Massachusetts A.B. History & Philosophy of Science (magna cum laude)	1973-1977
Centre d'Etudes Superieures de la Civilisation Medievale Universite de Poitiers Poitiers, France	1977-1978
Albert Einstein College of Medicine Bronx, New York M.D.	1978-1982

POST DOCTORAL TRAINING:

Intern	Department of Medicine Bellevue Hospital/NYU School of Medicine New York, New York	1982-1983
Resident	Department of Medicine Bellevue Hospital/NYU School of Medicine New York, New York	1983-1985
	Research Fellow/Oncology Division of Oncology Department of Medicine Bellevue Hospital/NYU School of Medicine New York, New York	
Clinical Fellow/Hematology	Division of Hematology Department of Medicine Bellevue Hospital/NYU School of Medicine New York, New York	1986-1987
Clinical Fellow/Oncology	Division of Oncology Department of Medicine Bellevue Hospital/NYU School of Medicine New York, New York	1987-1988
Certificate Program in Bioethics & Medical Humanities	Montefiore Medical Center and New York University	2001-2002

LICENSURE AND CERTIFICATION:

New York State License # 156851 (active)	1984
Diplomate, American Board of Internal Medicine, Certificate # 1045181	1985
Diplomate, American Board of Internal Medicine, Medical Oncology # 1045181	1989
Colorado State License # 41614 (active)	2003

ACADEMIC APPOINTMENTS:

Teaching Assistant Department of Medicine Bellevue Hospital/NYU School of Medicine New York, New York	1982-1988
Attending Physician Department of Emergency Services Bellevue Hospital/NYU School of Medicine New York, New York	1985-1988
Instructor in Clinical Medicine Department of Medicine NYU School of Medicine New York, New York	1988-1991
Assistant Professor of Clinical Medicine Department of Medicine NYU School of Medicine New York, New York	1991-1997
Clinical Associate Professor of Medicine Department of Medicine NYU School of Medicine New York, New York	1997-present
Masters Scholars Program Humanities and Medicine NYU School of Medicine New York, New York	2001-present
Visiting Professor – Humanities Farrand Program University of Colorado Boulder, Colorado	2004
Adjunct Instructor – Health Law School of Law University of Colorado Boulder, Colorado	2004
Firm Chief, Austin Flint Firm Department of Medicine NYU School of Medicine New York, New York	2006-present

HOSPITAL APPOINTMENTS:

Clinical Assistant Attending Physician Department of Medicine Bellevue Hospital Center New York, New York	1988-1996
Attending Physician Department of Medicine Bellevue Hospital Center New York, New York	1997-present
Attending Physician Department of Medicine New York VA Medical Center New York, New York	1988-present
Attending Physician New York University Hospital New York, New York	1988-present
Attending Physician Rocky Mountain Cancer Centers Rose Medical Center Denver, Colorado	2003-2005

AWARDS AND HONORS:

Rotary Foundation Graduate Fellowship	1977-1978
Alpha Omega Alpha	1981
Commonwealth Fellow, President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research	1981
Citation for Scholastic Excellence American Medical Women's Association	1982
American Cancer Society Regular Clinical Fellowship	1985
Public Health Service National Research Service Award	1985-1987
Kaplan Cancer Center Research Fellow	1987-1988
American Society of Clinical Oncology Travel Award	1988

American Cancer Society Career Development Award	1990
Fellow, American College of Physicians	1991
Honoree, Republic National Bank Breast Cancer Foundation	1997
NYU 1841 Society Lecturer	1997
Honoree, <i>CancerCare</i>	2002, 2004
Physician of the Year <i>CancerCare</i>	2005

COMMITTEES:

Harvard-Radcliffe Schools Committee Alumni Admissions New York City	1984-1999
Bellevue Hospital Ethics Committee	1987-1992
New York University Medical Center Peer Review Committee	1990-1996
Medical Consultant Cancer Care New York City	1992-present
New York University Medical Center Quality Assurance Committee	1992-1995
New York University School of Medicine Tisch Hospital Institutional Review Board	1993-2001
New York University School of Medicine Kaplan Cancer Center Director, Shared Resource Clinical Research Resources	1993-1999
New York University School of Medicine Kaplan Cancer Center Clinical Executive Management Committee	1991-2002

New York University Medical Center Medical Board Sub-committee on Legal Defense	1993-1999
New York University Medical Center Medical Board Ad-Hoc Committee on Professional Conduct	1994
New York University School of Medicine Kaplan Cancer Center Search Committee for Cancer Center Director	1996-1998
New York University Medical Center Medical Board Ad-Hoc Committee on Professional Conduct	1996
New York University Medical Center Tisch Hospital Medical Ethics Committee (Chairman	1998 - 2002 2005 - 2006 1999 – 2002)
New York University Medical Center Executive Committee Medical Board	2000- 2002
New York University School of Medicine Department of Medicine Search Committee for Tisch Hospital Chief of Medical Service	2000
New York University School of Medicine Clinical Appointments and Promotion Committee Of the Department of Medicine	2001- 2002
Harvard-Radcliffe Schools Committee Alumni Admissions Boulder, CO	2002 - 2004
Rose Medical Center Cancer Committee Denver, CO	2003-2005
US Oncology Rocky Mountain Cancer Centers Breast Cancer Research Committee	2003-2005
Denver Medical Society Public School Outreach	2003-2005

University of Colorado Conference on World Affairs Co-Chair Health & Medicine Committee	2003-2005
Bellevue Literary Review	2004-present
Executive Committee Department of Medicine NYU School of Medicine	2006-present

PROFESSIONAL SOCIETIES/MEMBERSHIPS:

American College of Physicians	1985 - 1990
Fellow, American College of Physicians	1990 - present
American Society of Clinical Oncology	1988 - present
Eastern Cooperative Oncology Group	1988 - present
New York State Medical Society	1989 – 2002 2005-present
New York County Medical Society	1989-2002 2005-present
New York State Society of Medical Oncologists	1989 - 2002
American Association for Cancer Research	1990 - present
New York Metropolitan Breast Cancer Group	2000 - 2002
American Society of Law, Medicine & Ethics	2002 – present
Colorado Medical Society	2003 - 2005
Denver Medical Society	2003- 2005
American Medical Association	2005 – present
Clerkship Directors in Internal Medicine	2007-present

ACADEMIC/TEACHING ACTIVITIES:

Attending Physician/Preceptor Third Year Medicine Clerkship Department of Medicine NYU School of Medicine	1988-1999 2005 - present
Preceptor Second Year Physical Diagnosis Department of Medicine NYU School of Medicine	2000-2001 2006-2007
Mentor First Year Medical Students Physician, Patient Society Course NYU School of Medicine	2001 2005 - present
Attending Physician Division of Oncology Fellowship Training Program Department of Medicine NYU School of Medicine	1988-2002 2005 - present
Lecturer for Housestaff Conferences, Morning Report and Student Conferences Medical Student Electives Mentor Department of Medicine NYU School of Medicine	1988-2002 2005-present
CME Lectures – Melanoma and Breast Cancer NYU School of Medicine Medical School Advisor First, Second, and Third Year Classes	1988-present 1990-1994 2005-present
Mentor – NYU School of Medicine Department of Medicine Residency Program	2002
Firm Chief, Austin Flint Firm Department of Medicine NYU School of Medicine	2006-present
Seminar Leader NYU School of Medicine Masters Scholars Program	2001-2003 2005 -2008

Panelist, Conference on World Affairs University of Colorado Boulder, Colorado	2002, 2005
University of Colorado Health Sciences Center Ethics in the Health Professions Small Group Facilitator	2003
Visiting Professor, Humanities Farrand Program University of Colorado Boulder, Colorado	2004
Adjunct Instructor – Health Law University of Colorado School of Law Boulder, Colorado	2004

ADVISORY BOARDS:

Eugene Zitwer Foundation	1993-present
Sharsheret : Linking Young Jewish Women in Their Fight Against Breast Cancer	2002- present
Cancer and Careers (Cosmetic Executive Women)	2002 – present
Susan G. Komen For the Cure Greater New York City Affiliate	2008-present
Day of Caring – Invited Speaker Denver, Colorado	2003, 2004
Cancer League of Colorado Scientific Advisory Board	2003 - 2005
Doctors for Kerry National Steering Committee Colorado	2004
Professional Advisory Board Breastcancer.org	2005 – present
Healthcare Review Committee The Lehman Brothers Foundation	2005

Oratz CV

Medical & Research Advisory Board Metastatic Breast Cancer Network	2006-present ¹⁰
Medical Advisory Board Living Beyond Breast Cancer	2006-present
Scientific Advisory Board Israel Cancer Research Fund	2007 - present
Girls Learn International	2007-present
Advisory Board Princeton in Asia	2008
Steering Committee Metastatic Breast Cancer Patient Survey	2008

PUBLICATIONS:

1. Oratz R. The plague - Changing notions of contagion: London 1665 - Marseille 1720. *Synthesis*. 4:4-28, 1977.
2. Zolla-Pazner SC, Koehne C, Oratz R. Humoral mediator of antigenic competition demonstrated in vivo. *Int Arch All App Immunol*. 59:349-356, 1979.
3. Oratz R. Achieving aesthetic distance: Education for an effective doctor-patient relationship in making health care decisions. Vol. III. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Washington, DC, 1982.
4. Chachoua A, Oratz R, Green M, Muggia F. Acquired Immune Deficiency Syndrome. In: Pinedo HM, Chabner BA, (Eds). *Cancer Chemotherapy* 8. New York: Elsevier Science Publishers. 305-32, 1986.
5. Oratz R. "Immunotherapy for Malignant Melanoma: Interferons". *The Melanoma Letter*, Skin Cancer Foundation. Vol 4, No 2, 1986.
6. Chachoua A, Oratz R, Green M, Muggia F. Acquired Immune Deficiency Syndrome. In: Baldwin, (Ed). *Immunology of Malignant Disease*, MTP Press. pp. 225-261, 1987.
7. Guidelines on the Termination of Life-Sustaining Treatment and the Care of the Dying. The Hastings Center. 1987.
8. Oratz R, Speyer JL, Green M, Blum R, Wernz JC, Muggia FM. Treatment of Metastatic Malignant Melanoma with Dacarbazine and Cisplatin. *Cancer Treat Rep*. 71:877-878, 1987.
9. Green M, Oratz R, Muggia FM. Carcinoid Syndrome from a Tumor of Meckel's Diverticulum. *Amer J of Med*. 83:184-186, 1987.
10. Oratz R, Chachoua A, Speyer J. Intraperitoneal therapy in gastrointestinal malignancies. *Advances in Oncology*. 3:23-29, 1987.
11. Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Humans. *Cancer*. 61:1065-1070, 1988.
12. Bystryn JC, Dugan M, Oratz R, Speyer J, Harris MN, Roses DF. Vaccine immunotherapy of human malignant melanoma. In: "Human Tumor Antigens and Specific Tumor Therapy." UCLA Symposia on molecular and cellular biology, New Series. RM Etzgar and M Mitchell (Eds). Alan R Liss, Inc. New York, NY. pp. 307-315, 1989.
13. Oratz R, Cockerell C, Speyer JL, Harris M, Roses D, Bystryn JC. Induction of tumor infiltrating lymphocytes in malignant melanoma metastases by immunization to melanoma antigen vaccine. *Journal Biol Resp Mod*. 8:355-358, 1989.
14. Oratz R, Chachoua A, Green M. Principles in chemotherapy. In: Rosenthal CJ, (Ed). *Manual of Clinical Oncology*. 1989.

15. Oratz R, Speyer JL, Wernz SC, Hochster H, Meyers M, Mischak R, and Spitler LE. Antimelanoma Monoclonal Antibody-Ricin A Chain Immunoconjugate (XMMME-001-RTA) Plus Cyclophosphamide in the Treatment of Metastatic Malignant Melanoma: Results of a Phase II Trial. *Journal Biol Resp Mod.* 9:345-354, 1990.
16. Bystryn J-C, Oratz R, Harris MN, Roses DF, Speyer J. Potentiation of immune response to a melanoma antigen vaccine. In: *Vaccine: New Concepts and Developments.* H. Kohler and PT Loverde (Eds). John Wiley and Sons. New York, pp 438-439, 1989.
17. Dugan M, Oratz R, and Bystryn J-C. Immunotherapy in the treatment of malignant melanoma. In: *Cancer of the Skin.* RF Friedman (Ed). WB Sanders. Chapter 38, pp. 569-579, 1990.
18. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J, Boyd A, Golomb FM, Ransohoff J, Dugan M, Valentine FT, Cooper J, and Bystryn J-C. Survival with regional and distant metastases from cutaneous malignant melanoma. *Surg Gynecol Obst.* 172:262-268, 1991.
19. Bystryn JC, Oratz R. Malignant melanoma. In: *Dermatologic diseases of the skin.* RE Jordan (Ed). Appleton and Lange, 1991.
20. Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn J-C. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. *Cancer Res.* 51:3643-3647, 1991.
21. Oratz R and Bystryn J-C. Immunotherapy of malignant melanoma. *Dermatologic Clinics.* 9:669-682, 1991.
22. Bystryn J-C, Oratz R, Roses D, Harris M, Henn M, and Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in Stage II malignant melanoma. *Cancer.* 69:1157-1164, 1992.
23. Walsh C, Blum RH, Oratz R, Goldenberg A, Downey A, Speyer JL. Phase I study of doxorubicin, ICRF-187 and granulocyte macrophage colony stimulating factor (GM-CSF). *J Can Res Clin Onc.* 118:61-66, 1992.
24. Liebes L, Walsh C, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, Le Sher D, Blum R, and Vilcek. Modulation of monocyte tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. *J Natl Cancer Inst.* 84:694-699, 1992.
25. Hochster H, Liebes L, Wadler S, Lewis R, Oratz R, Wernz JC, Meyers M, Green M, Reynolds R, Narang PK, Blum RH, Speyer JL. Toxicity and pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. *J. Natl. Cancer Inst.* 84:1725-1730, 1992.
26. Hochster H, Liebes L, Wadler S, Oratz R, Wernz J, Meyers M, Green M, Blum R, Speyer J. Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. *J Natl Cancer Inst.* 84:1725-1730, 1992.

27. Oratz R, Speyer JL, Blum RH, Wernz JC, Levin M, Lonberg M, Harris M, Roses D, Muggia FM. 5 year follow-up of adjuvant chemotherapy (AC) of malignant melanoma (MM) with DTIC and Actinomycin-D (Act-D). Submitted to the American Radium Society.
28. Bystryn JC, Shapiro RL, Roses DF, Oratz R. Melanoma vaccines. *Hem/Onc Ann.* 1(4):301-307, 1993.
29. Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, and Blum RH. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. *Journal of Immunotherapy.* 16:132-141, 1994.
30. Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, and Vilcek J. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. *Journal of Immunotherapy.* 15:217-224, 1994.
31. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, and Blum RH. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active well-tolerated regimen. *Journal of Clinical Oncology.* 12(3):553-559, 1994.
32. Cui J, Chen D, Oratz R, Zeleniuch-Jacquotte A, Harris M, Roses D, Bystryn J-C. Induction of cytolytic antibodies to melanoma by immunization to a polyvalent melanoma antigen vaccine. *Vaccine Res.* 13(4):175-182, 1994.
33. Oratz R, Blum R. Clinical update: Malignant melanoma, chemotherapy. *Advances in Oncology.* 10(4):26-29, 1994.
34. Bystryn JC, Oratz R, Shapiro R. Cancer vaccines: Clinical applications, partially purified tumor antigen vaccines. In: *Biologic Therapy of Cancer.* VT DeVita, Jr, S Hellman, SA Rosenberg (Eds). JB Lippincott Co. pp. 668-679, 1995.
35. Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn J-C. Effect of DETOX as an adjuvant for melanoma vaccine. *Vaccine.* 13(5):503-508, 1995.
36. Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris M, Bystryn J-C. Improved survival of melanoma patients with an antibody response to immunization to a polyvalent melanoma vaccine. *Cancer.* 75(2):495-502, 1995.
37. Adler A, Oratz R, Bystryn J-C. In vitro cell-mediated immune response induced by a polyvalent allogeneic melanoma vaccine. *Cancer Biother.* 10(3):2121-224, 1995.
38. Bystryn J-C, Oratz R, Shapiro R, Johnston D, Harris M, Roses D, Zeleniuch-Jacquotte A, Chen DL, Lax A. Potentiation of melanoma vaccine activity by IL-2 liposomes. *J Invest Derm.* 106(4):845 (235), 1996.
39. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, and Speyer J. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An Active regimen with limiting neurotoxicity. *J Clin Oncol.* 14:1993-1999, 1996.

40. Oratz R, Bystryn J-C. Malignant Melanoma. In: Immunomodulatory and Cytotoxic Agents in Dermatology. CJ McDonald (Ed). Marcel Dekker, New York, NY. In press.
41. Bystryn J-C, Shapiro RL, Harris M, Roses DF, Oratz R. The use of vaccines in the treatment of malignant melanoma. *Clin Dermatol.* 14(4):337-41, 1996.
42. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a Phase I and pharmacodynamic study. *Clin Cancer Res.* 3(8):1245-52, 1997.
43. Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro RL, Bystryn J-C. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. *J Natl Cancer Inst.* 90:146-9, 1998.
44. Rosenthal MA, Dennis D, Liebes L, Furmanski P, Caron D, Garrison L, Wiprovnick J, Peace D, Oratz R, Speyer J, and Chachoua A. Biologic activity of Interleukin 1 (IL-1) alpha in patients with refractory malignancies. *J Immunother.* 21(5):371-378, 1998.
45. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, and Bystryn J-C. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. *J Immunology.* 161:6970-6976, 1998.
46. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. *Am J Clin Oncol.* 21(4):352-4, 1998.
47. Hochster H, Oratz R, Ettinger DS, and Borden E. A Phase II study of didemnin B (NSC 325319) in advanced malignant melanoma: An Eastern Cooperative Oncology Group study (PB687). *Invest New Drugs.* 16:259-263, 1999.
48. Shapiro RL, Oratz R, and Roses DF. Treatment of Regionally recurrent malignant melanoma. *Advances in Oncology.* 15(4):15-21, 1999.
49. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn J-C. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. *J Immunol Methods.* 20:244(1-2):59-67, 2000.
50. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment. *Clin Cancer Res.* 6(12):4610-7, 2000
51. Bystryn JC, Albrecht J, Reynolds SR, Rivas MC, Oratz R, Shapiro RL, Roses DF, Harris MN, Conrad A. Decrease in circulating tumor cells as an early marker of therapy effectiveness. *Recent Results Cancer Res.* 158:204-7, 2001.
52. Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF. Elective radiation therapy for high-risk malignant melanomas. *Cancer Journal.* 7(6):498-502, 2001.

53. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, and Symmans WF. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. *Clin Cancer Res.* 7(10):3025-30, 2001.
54. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. *Clin Cancer Res.* 7(7):1882-7, 2001.
55. Oratz, R Hauschild, Sebastian Schadend Castro, Brocker, Orenberg; Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma; *Melanoma Res 2003 Feb;13(1):59-66* (pmid: 12569286)
56. “Trip to Jewish Cuba: a diary of Dr. Ruth Oratz Ridless” www.thecajm.org 2003
57. “Ask Us Anything” web column for www.cancerandcareers.org/women/working/ April 2004 – present
58. Stone, A Cooper, Koenig, Golfinos Oratz, R; A comparison of survival rates for treatment of melanoma metastatic to the brain; *Cancer Invest 2004;22(4):492-7* (pmid: 15565805)
59. Guglielmino JE, Simmons JC, Black L, Caplan ES, Grillo A, Sachs J, Oratz, R et al.. Living Beyond Breast Cancer’s Guide for the Newly Diagnosed. LBBC 2006
60. Oratz R, Paul Dev, Cohn Allen, Sedlacek, Scot. Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer. *Journal of Oncology Practice* 3(4):182-186, 2007.
61. Andrenopoulou E, Gaiotti D, Volm M, Oratz R, Freedberg R, Downey A, Vogel C, Chia S, Muggia, F. Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER-2 Overexpressing Metastatic Breast Cancer. *Clin Breast Cancer.* 2007 Aug; 7 (9) 690-
62. Guglielmino JE, Simmons JC, Black L, Caplan ES, Grillo A, Sachs J, Oratz, R et al.. Living Beyond Breast Cancer’s Guide to Understanding Your Emotions

ABSTRACTS:

1. Bystryn JC, Oratz R, Harris M, Roses D, Speyer J. Cellular immune response to a melanoma antigen vaccine. *Proc Amer Fed Clin Res* 1986.
2. Bystryn JC, Oratz R, Harris M, Roses D, Speyer J. Potentiation of immune response to a melanoma antigen vaccine. International Conference on Cancer. Budapest, Hungary, 1986.

3. Oratz R, Speyer JL, Blum RH, Wernz JC, Levin M, Lonberg M, Harris M, Roses D, Muggia FM. 5 year follow-up of adjuvant chemotherapy (AC) of malignant melanoma (MM) with DTIC and Actinomycin-D (Act-D). Submitted to the American Radium Society.
4. Oratz R, Cockerell C, Speyer J, Roses DF, Harris MN, Bystryn JC. Induction of Lymphocytic Cell Infiltrate in Human Melanoma Nodules by Active Immunization to Melanoma Antigen Vaccine. *Proc Amer Assoc Can Res* 28:1482A, 1987.
5. Oratz R, Speyer JL, Green MD, Blum R, Wernz J, Roses D, Harris M, Muggia FM. DTIC and Cis-Platinum Chemotherapy in Metastatic Malignant Melanoma. *Proc Amer Soc Clin Onc.* 6:820A, 1987.
6. Dugan M, Oratz R, Speyer J, Roses DF, Harris MN, Golomb F, Bystryn JC. Relationship Between Immune Responses to Melanoma Vaccine Immunization and Tumor Progression in Man. *Proc Amer Fed Clin Res.* 35:523A, 1987.
7. Oratz R, Speyer J, Spitler L, Mischak R. Immunotoxin and cyclophosphamide in malignant melanoma. *Proc Am Soc Clin Onc.* 7:981A 1988.
8. Dugan M, Oratz R, Harris MN, et al. Delayed tumor progression in melanoma patients with cellular immune response to melanoma vaccine. *Proc Amer Fed Clin Res.* 36:495A, 1988.
9. Bystryn JC, Dugan M, Oratz R, Speyer J, Roses DF, Harris MN. Potentiation of human melanoma vaccine: Relation between method of immunization, immunogenicity, and tumor progression. *J of Cellular Biochemistry.* 12E, 202T, 1988.
10. Oratz R, Speyer J, Wernz J, Hochster H, Meyers M, Blum R, Mischak R, Spitler LE, Ackerman S. Activity of an anti-melanoma monoclonal antibody-Ricin A chain immunotoxin (IT) and cyclophosphamide (CTX) in metastatic malignant melanoma (MMM). Society of Biological Therapy, Berkeley, CA, November, 1988.
11. Oratz R, Dugan M, Harris M, Roses D, Speyer JL, Hochster H, Henn M, Blum RH, Bystryn JC. A randomized trial of an adjuvant polyvalent melanoma antigen vaccine with or without cyclophosphamide in patients with malignant melanoma. *Proc Am Soc Clin Onc.* 8:288, 1989.
12. Oratz R, Dugan M, Walsh C, Hochster H, Meyers M, Wernz J, Speyer JL, and Blum RH. Phase II trial of r-a2b-interferon (IFN) and cisplatin (CDDP) in metastatic malignant melanoma (MM). *Proc Am Soc Clin Onc.* 8:288, 1989.
13. Walsh C, Chachoua A, Hochster H, Downey A, Wood D, Nadler P, Speyer J, Wernz J, Oratz R, Meyers M, and Blum RH. Phase I study of recombinant human tumor necrosis factor (rHTNF). *Proc Am Soc Clin Onc.* 8:193, 1989.
14. Richards D, Walsh C, Oratz R, Hochster H, Speyer JL, Liebes L, Kanganis D, Alba S, Le Sher D, Jacquotte-Zeleniuch A, Blum RH. TNF induction in a Phase II trial of a liposome encapsulated synthetic muramyl tripeptide (CGP 19835A) in metastatic melanoma. Society of Biological Therapy, 1989.
15. Hoogmoed RP, Chachoua A, Dunleavy SE, Liebes LF, Kanganis D, Oratz R, Speyer JL, Wernz JC, Meyers MI, Weissman J, Walsh CM, Hochster HS, Le J, Vilcek J, and Blum RH.

- Oratz CV
Phase Ib study of GM-CSF as a monocyte activator in adult cancer patients. Proc Am Soc Clin Onc. 9:747, 1990. 17
16. Speyer JL, Walsh CM, Downey A, Hochster H, Oratz R, Goldenberg A, Chachoua A, and Blum RH. A Phase I trial of escalating doxorubicin with ICRF-187 for cardioprotection and GMCSF for bone marrow support. Proc Am Soc Clin Onc. 9:161, 1990.
 17. Hochster H, Oratz R, Wernz J, Speyer J, Meyers M, Chachoua A, Walsh C, Dunleavy S, Blum R, Kreis W, Nadler P, Spigelman MK. Weekly amonafide: Phase I study of a novel schedule. Proc Am Soc Clin Onc. 9:265, 1990.
 18. Hochster H, Speyer J, Liebes L, Oratz R, Meyers M, Alba S, Wadler S, Reynolds R, Narang NK, Blum R. Phase I & Pharmacokinetic study of escalating ADR-529 (ICRF-187) with doxorubicin (AdriamycinR). Proc Am Soc Clin Onc. 9:318, 1990.
 19. Liebes L, Walsh C, Adler A, Richards D, Kanganis D, Oratz R, Leshner D, Blum R. Evaluation of monocyte functional activity and phenotypic expression following in vivo administration of muramyl tripeptide in liposomes (CGP 19835A). Proc Am Assoc Cancer Res. 31:1453, 1990.
 20. Adler A, Oratz R, Liebes L, Bystryjn JC. Effect of allogeneic melanoma vaccine on the in vitro cellular immune responses. Proc Am Assoc Cancer Res. 31:1491, 1990.
 21. Li J, Henn M, Oratz R, Bystryjn J-C. The antibody response to immunization to a polyvalent melanoma antigen vaccine. Clin Res. 38:600A, 1990.
 22. Bystryjn JC, Li J, Henn M, Oratz R. Identification of immunogenic antigens in a polyvalent melanoma antigen vaccine. Proc Am Assoc Cancer Res. 31:1657, 1990.
 23. Bystryjn J-C, Oratz R, Harris MN, Roses DF, Henn M. The DTH response to melanoma vaccine immunization. J of Cellular Biochemistry. Supp 14B:105, 1990.
 24. Chapnick J, Noz ME, Kramer E, Sanger J, Birnbaum B, Maguire GQ, Megibow A, Oratz R, Weinreb J, Martino J. Structural/functional image fusion in cancer patients. Space - RSNA. Chicago, November 25-30, 1990.
 25. Cho J, Oratz R, Harris M, Roses D, Henn M, Bystryjn J-C. Induction of cytolytic melanoma antibodies by immunization to a polyvalent melanoma antigen vaccine. Proc Amer Assoc Cancer Res. 32:1520, 1991.
 26. Bystryjn J-C, Oratz R, Harris MN, Roses DF, Henn M, Lew R. Improved survival of melanoma patients with delayed type hypersensitivity response to melanoma vaccine immunization. Clin Res. 39:503A, 1991.
 27. Oratz R, Roses D, Harris M, Zeire E, Bystryjn JC. Effect of detox on the immunogenicity of a melanoma vaccine. Proc Am Soc Clin Onc. 10:1038, 1991.
 28. Schultz NR, Oratz R, Chen L, Bystryjn JC. Effect of detox on the antibody response to a polyvalent melanoma antigen vaccine in man. Fourth World Congress on Cancers of the Skin. New York, April 18-20, 1991.

29. Schultz N, Oratz R, Chen D, and Bystryn J-C. Effect of detoxTM on the immunogenicity of polyvalent melanoma antigen vaccine in man. *Proc Am Soc Clin Onc.* 11:1180, 1992.
30. Dennis D, Chachoua D, Caron D, Garrison L, Liebes L, Furmanski P, Wiprovnick J, Peace D, Oratz R, Speyer J, Blum RH. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies. *Proc Am Soc Clin Onc.* 11:830, 1992.
31. Felice AJ, Chachoua A, Oratz R, Caron D, Peace D, Liebes LF, Hochster HS, Vilcek J, Lafleur F, and Blum RH. A Phase IB trial of GM-CSF with murine monoclonal antibody R24 in patients with metastatic melanoma. *Proc Am Soc Clin Onc.* 11:1188, 1992.
32. Hochster H, Speyer J, Oratz R, Meyers M, Wernz J, Chachoua A, Raphael B, Lee R, Sorich J, Taubes B, Liebes L, Fry D, Blum R. Topotecan 21 day continuous infusion - Excellent tolerance of a novel schedule. *Proc Am Soc Clin Onc.* 12:356, 1993.
33. Miller K, Abeles G, Oratz R, Cui J, Roses DF, Harris MN, and Bystryn J-C. Prolongation of survival of melanoma patients with antibody response to immunization with a polyvalent melanoma. *Proc Am Soc Clin Onc.* 12:1353, 1993.
34. Blum RH, Powers TV, Downey AM, Prasad N, Oratz R, Friedberg DN, Kuca BX, Kaye JA. rhM-CSF for adult soft tissue sarcoma (ASTS). *Proc Am Soc Clin Onc.* 12:1655, 1993.
35. Bystryn J-C, Miller K, Cui J, Oratz R. Identification of candidate antigens for construction of melanoma vaccines. *Clin Res.* 41(2):489A, 1993.
36. Hochster H, Speyer J, Oratz R, Meyers M, Wernz J, Chachoua A, Raphael B, Lee R, Sorich J, Taubes B, Liebes L, Fry D, Blum R. Novel schedule for administration of topotecan (TPT): 21 day low dose continuous infusion (CI). Submitted for ECCO meeting in Jerusalem, November 1993.
37. Bystryn J-C, Oratz R, Harris MN, Roses DF. Clinical activity of a polyvalent melanoma vaccine. *J Invest Dermatol.* 101(3):396, 1993.
38. Bystryn J-C, Miller K, Abeles G, Oratz R, Roses DF, Harris MN. Improved survival of melanoma patients with antibody responses to a polyvalent melanoma vaccine. *Melanoma Res.* 3:51, 1993.
39. Adler A, Oratz R, Bystryn J-C. Characterization of in vitro cellular immune responses induced by a polyvalent melanoma antigen vaccine. *Specific Immunotherapy of Cancer with Vaccines.* Washington, DC, 1993.
40. Miller K, Abeles G, Oratz R, Bystryn J-C. Characterization of candidate human melanoma antigens for vaccine construction. *Specific Immunotherapy of Cancer with Vaccines.* Washington, DC, 1993.
41. Bystryn J-C, Oratz R, Harris MN, Roses DF, Perelman RO. Clinically beneficial immune responses to melanoma vaccine treatment. *Melanoma Res.* 3(Suppl 1):30, 1993.
42. Wasserheit C, Alter R, Speyer J, Hochster H, Oratz R, Wernz J, Chachoua A, Meyers M, Sorich J, Downey A, Friedberg A, Blum R. Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer. *Proc Am Soc Clin Onc.* 13:204, 1994.

43. Oratz R, Shapiro R, Chen D, Harris M, Roses D, Bystryn J-C. Effect of IL-2 liposomes on the immunogenicity of a polyvalent melanoma antigen vaccine. *Proc Am Soc Clin Onc.* 13:1350, 1994.
44. Bystryn JC, Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Roses DF, Harris MH, Perelman RO. Mechanism of action of melanoma vaccines. *Proc Am Soc Clin Onc.* 13:976, 1994.
45. Hochster H, Speyer J, Oratz R, Meyers M, Sorich J, Taubes B, Vinci RZ, and Blum RH. Phase I study of taxol with 14-day topotecan continuous low-dose infusion. *Proc Am Soc Clin Onc.* 14:1586, 1995.
46. Oratz R, Roses D, Harris M. Alpha-interferon and cis-retinoic acid in the treatment of metastatic malignant melanoma. *Proc Am Soc Clin Onc.* 14:1313, 1995.
47. Hochster H, Liebes L, Zeleniuch-Jacquotte A, Speyer J, Oratz R, Wernz J, Sorich J, Taubes B, Vinci RZ, Kim A, Fry D, Blum R, and Potmesil M. Progressive cleavable complex formation with 21-day topotecan infusion: A Phase I/pharmaco-dynamic study. *Proc Am Soc Clin Onc.* 14:1496, 1995.
48. Wasserheit C, Chachoua A, Hochster H, Oratz R, Downey A, Farrell K, Simpson K, Blum R. Phase I study of edatrexate, doxorubicin and G-CSF in patients with solid tumors. *Proc Am Soc Clin Onc.* 14:1587, 1995.
49. Frazein A, Wasserheit C, Hochster H, Oratz R, Wernz J, Chachoua A, Meyers M, Sorich J, Downey A, Blum R, Speyer J. High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer. *Proc Am Soc Clin Onc.* 14:145, 1995.
50. Bystryn JC, Oratz R, Shapiro R, Roses D, Harris M, Johnston D. Vaccine treatment of melanoma. *Proceedings of the 38th Clinical Conference: Advances in the Biology and Clinical Management of Melanoma.* The University of Texas MD Anderson Cancer Center. February 21-24, 1995.
51. Hochster H, Potmesil M, Liebes L, Sorich J, Taubes B, Dewey D, Oratz R, and Speyer J. Extended 9-AC Infusion: A Phase I study. *Proceedings of the European Cancer Center Symposium on DNA Topoisomerase.* September 1995.
52. Bystryn J-C, Oratz R, Shapiro R, Johnston D, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Chen DL, Lax A. Potentiation of melanoma vaccine activity by IL-2 liposomes. *J Invest Derm.* 106(4):845(235), 1996.
53. Dosik D, Chachoua A, Oratz R, Shapiro R, Speyer J, Wasserheit C, Frazein A, Downey A, Blum R. Phase I study of IL-1a combined with high dose cisplatin (CDDP) in patients (pts) with metastatic melanoma. *Proc Am Soc Clin Onc.* 15: 440, 1996.
54. Hochster H, Liebes L, Z-Jacquotte A, Sorich J, Speyer J, Oratz R, Chachoua A, Blum R, Taubes B, Ludwig E, Kim A, Fry D, Broom C. Pharmacodynamics of 21-day topotecan infusion in a Phase II study of ovarian cancer: Correlation with TPT administration and heme toxicity. *Proc Am Soc Clin Onc.* 15:476, 1996.

55. Oratz R, Goldenberg A, Rosen R, Rofsky N. Chemoembolization for hepatic metastases in malignant melanoma. *Proc Am Soc Clin Onc.* 15:440, 1996.
56. Oratz R, Shapiro R, Johnston D, Harris M, Roses D, Zeleniuch-Jacquotte A, Chen D, Lax A, Bystryn JC. IL-2 liposomes markedly enhance the activity of a polyvalent melanoma vaccine. *Proc Am Soc Clin Onc.* 15:436, 1996.
57. Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, Chachoua A, Sorich J, Taubes B, Ludwig E, Broom C, Blum R. Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: A highly active regimen (A NYGOG Study). *Proc Am Soc Clin Onc.* 15:285, 1996.
58. Reynolds SR, Vukmanovic S, Oratz R, Shapiro RL, Bystryn J-C. A polyvalent melanoma vaccine induces a CD8 T cell response to MART-1 and MAGE-3 peptides. *Proc Am Assoc Cancer Res.* 37:491, 1996.
59. Bystryn J-C, Oratz R, Shapiro R, Reynolds S, Johnston D, Harris M, Roses D, Zeleniuch-Jacquotte A. Polyvalent melanoma antigen vaccine. *Cambridge Symposia "Immunology and Immunotherapy of Metastasis"*, Lake Tahoe, 1996.
60. Bystryn J-C, Oratz R, Shapiro R, Johnston D, Reynolds S, Harris M, Roses D, Zeleniuch-Jacquotte A. Potentiation of melanoma vaccine immunogenicity by IL-2 liposomes. *Cambridge Symposia "Discovery and Development of Tumor Vaccines"*, Taos, 1996.
61. Wasserheit C, Oratz R, Downey A, Speyer J, Wernz J, Takashita K, Mills N, Cohen J, Liebes L, Muggia F. Phase I trial of 9-cis retinoic acid (LGD-1057, NSC# 659772) and Tamoxifen in patients with metastatic carcinoma of the breast. *Proc Am Soc Clin Onc.* 16:695, 1997.
62. Hochster H, Wasserheit C, Siddiqui N, Sorich J, Downey A, Wernz J, Oratz R, Meyers M, Moskovits T, and Speyer J. Vinorelbine/cisplatin therapy of locally advanced and metastatic breast cancer: An Active Regimen. *Proc Am Soc Clin Onc.* 16:606, 1997.
63. Oratz R, Reynolds SR, Shapiro RL, Harris M, Roses D, Vukmanovic S, Bystryn J-C. A polyvalent melanoma vaccine induces MAGE-3 and MART-1/melan-A specific CD8+ T cell responses that correlate with clinical outcome. *Proc Am Soc Clin Onc.* 16:1548, 1997.
64. Oratz R, Reynolds S, Shapiro RL, Harris MN, Roses DF, Johnston D, Jacquotte A, Hankinson T, Bystryn J-C. Phase I/II trial of a shed, polyvalent, melanoma vaccine combined with interferon alfa-2b in stage IV melanoma. *Proc Am Soc Clin Onc.* 17:2009, 1998.
65. Klein P, Lyass O, Sorich J, Wasserheit C, Hochster H, Chachoua A, Speyer JL, Oratz R, Lafair J, Downey A, Kotcher L, Muggia F, Gabizon A. Doxil plus cisplatin: Combined results of two Phase I studies. *Proc Am Soc Clin Onc.* 17:942, 1998.
66. Bystryn J-C, Oratz R, Shapiro RL, Harris MN, Roses DF, Jacquotte A, Chen DL, Rivas M. Phase 3, double-blind, trial of a shed, polyvalent, melanoma vaccine in stage III melanoma. *Proc Am Soc Clin Onc.* 17:1673, 1998.

67. Oratz R, Sebastian G, Hauschild A, Reiss H, Castro D. Intratumoral focused therapy with cisplatin/epinephrine gel as a palliative treatment of recurrent malignant melanoma. Submitted to the NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, June 16-19, 1998.
68. Wasserheit C, Downey A, Sorich J, Liebes L, Hochster H, Oratz R, Eisenberg T, Losev A, and Muggia FM. A Phase I study of taxotere and doxil in patients with advanced malignancies. *Proc Am Soc Clin Onc.* 18:642, 1999.
69. Klein P, Wasserheit C, Hochster H, Chachoua A, Speyer JL, Oratz R, Downey A, Sorich J, Kotcher L, Eisenberg T, Muggia F. Apparent protection of doxil skin and oral toxicities when combined with cisplatin (CDDP): Results of a Phase I study. *Proc Am Soc Clin Onc.* 18:835, 1999.
70. Rosenthal MA, Oratz R, Liebes L, Cahr MH, Muggia FM. Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies. *Proc Am Soc Clin Onc.* 18:873, 1999.
71. Volm MD, Yee H, Symmans WF, Formenti S, Oratz R, Shapiro R, McMullen H, Shore R, and Muggia F. HER2 status predicts response to preoperative paclitaxel in patients with breast cancer. *Proc Am Soc Clin Onc.* 18:394, 1999.
72. Harbord M, Brown S, Mishra L, Fernando I, Oratz R, Castro D, et al. Phase III trials of intratumoral cisplatin/epinephrine injectable gel for treatment of advanced solid tumors. *Proc Am Soc Clin Onc.* 18:738, 1999.
73. Bystryn J-C, Oratz R, Shapiro RL, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Chen DL, Rivas MC, Hankinson T. Double-blind, placebo-controlled trial of a shed, polyvalent, melanoma vaccine in Stage III melanoma. *Proc Am Soc Clin Onc.* 18:1673, 1999.
74. Shapiro RL, Johnston D, Oratz R, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Beck A, Bystryn J-C. Effect of GM-CSF liposomes on the immunogenicity of a polyvalent melanoma vaccine. *Proc Am Soc Clin Onc.* 18:1695, 1999.
75. Oratz R, Albrecht J, Shapiro RL, Harris MN, Roses DF, Chen DL, Rivas MC, Conrad A, Bystryn J-C. Assay of circulating melanoma cells as an indicator of the efficacy of melanoma vaccine therapy. *Proc Am Soc Clin Onc.* 18:2134, 1999.
76. Volm M, Oratz R, Pavlick A, Farrell K, Lee J, Muggia F. A Phase I study of liposomal doxorubicin and temozolomide in patients with advanced cancer. *Proc Am Soc Clin Onc.* 19:872, 2000.
77. Chodkiewicz C, Wasserheit C, Downey A, Sorich J, Liebes L, Phillips Z, Hochster H, Oratz R, Pavlick A, Speyer J, Friedman, Muggia F. Doxil (D) and docetaxel (Taxotere, T): Pharmacokinetic (PK) results at the recommended Phase II dose (RPTD). *Proc Am Soc Clin Onc.* 19:825, 2000.
78. Reynolds SR, Bystryn J-C, Albrecht J, Oratz R, Shapiro RL, Harris MN, Roses DF, Conrad A. Relation between melanoma vaccine therapy and decrease in circulating melanoma cells. *Proc Am Soc Clin Onc.* 19:2242, 2000.

79. Xie Z, Reynold S, Oratz R, Shapiro RL, Harris MN, Roses DF, Bystryn J-C. The IgM antibody response to melanoma vaccine immunization is an intermediate marker of clinical effectiveness. *Proc Am Soc Clin Onc.* 19:2192, 2000.
80. Bystryn J-C, Oratz R, Shapiro RL, Reynolds SR, Celis E, Sette A. Direct identification of melanoma-associated peptides that are immunogenic in vivo in humans by vaccine-induced immune response (VIIR) analysis. *Proc Am Soc Clin Onc.* 19:2190, 2000.
81. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti S, Muggia F, and Symmans WF. Increase in the lymphocyte infiltrate in breast cancer after neoadjuvant paclitaxel chemotherapy. *Proc Am Assoc Cancer Res.* 41:2120, 2000.
82. Liebes L, Hochster H, Speyer J, Chachoua A, Hamilton A, Oratz R, Pavlick A, Sorich J, Francois A, Muggia F. Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor, R115777: A Phase I & pharmacodynamic study. *Proc Am Soc Clin Onc.* 20:81a, abstract 321, 2001.
83. Pavlick AC, Hamilton A, Liebes L, Oratz R, Wadler S, Roberts J, Fry D, Roboz J, Farrell K, Dellenbaugh C, Muggia F. Bryostatins 1 and cisplatin: A Phase I and pharmacodynamic study. *Proc Am Soc Clin Onc.* 20:83a, abstract 328, 2001.
84. Amsterdam A, Schlossberg P, Goldenberg A, Oratz R. Chemoembolization (CE) with radio-frequency ablation (RFA) in metastatic tumors of the liver. *Proc Am Soc Clin Onc.* 21:2b part 2 abstract 1815, 2002
85. Pavlick AC, Oratz R, Bailes A, Farrell K, Volm, Muggia F. A Phase II trial of DTIC with Thalidomide in metastatic melanoma. *Proc Am Soc Clin Onc.* 21:349a part 1, abstract 1393
86. Fink M, Pavlick AC, Bailes A, Farrell K, Volm M, Oratz R, Muggia F. A phase II trial of DTIC with thalidomide in metastatic melanoma. *Proc Am Soc Clin Onc ASCO 2004.*
87. Mullineaux L, Oratz R, Paul D, Sedlacek S. Demographics of BRCA1/2 mutations in Colorado. Poster presentation/abstract Lynne Cohen Foundation Symposium. New York University School of Medicine, New York, New York. April 2004.
88. Oratz R, Renshaw G, O'Shaughnessy J. et al. A Phase II multicenter study of the Cyclin-dependent kinase inhibitor indisulam in patients with refractory advanced and/or metastatic breast carcinoma. *Proc Am Soc Clin Onc 2005.*
89. Oratz R, Paul D, Cohn A, Sedlacek S. Impact of Oncotype DX on decision making in breast Cancer clinical practice. *Proc. 28th Ann. San Antonio Breast Cancer Symposium Abstract # 2049 2005*
90. Bersson Y, Pearlman A, Shajahan S, Ostrer H, Oratz R. BRCA1 and BRCA2 mutations: 185delAG, 5382insC and 6174delT; Ashkenazi founder or Jewish determinant? *Proc 29th Ann. San Antonio Breast Cancer Symposium Abstract # 2006*

91. Oratz R, Paul D, Cohn A, Sedlacek S. Impact of a commercial reference laboratory test Recurrence Score on Decision Making in Early-Stage Breast Cancer. *J. Oncol. Pract.* 3:182-186, 2007.

92. Jones SE^{1,2}, Collea RP^{1,3}, Oratz R^{1,4}, Paul D^{1,5}, Sedlacek SM^{1,5}, Holmes FA^{1,6}, Portillo RM^{1,7}, Crockett MW¹, Asmar L¹, O'Shaughnessy JA^{1,2}, Robert N^{1,8}. Preliminary toxicity results of a Phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab in HER2+ early stage breast cancer patients. Submitted to SABC 2008